Company intelligence / Profile preview

Minimus Spine

Austin, Texas, United Statesthespinemarketgroup.com ↗

Ownership: Private
Employees: ~30
Development stage: Commercial

Overview

The Triojection System has received certifications for commercialization in Europe. Clinical studies have been conducted comparing its efficacy to surgical discectomy, aiming to demonstrate non-inferiority or superiority for treating lumbar disc herniations. The system delivers a controlled dose of ozone gas into the affected intervertebral disc, with the goal of reducing pain and avoiding surgery or steroid injections. No large-scale pivotal trial results are publicly available as of June 2025.

Therapeutic areas: Neurology
Modalities: Device (Triojection System)Ozone-based therapy (minimally invasive injection)
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Minimus Spine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Minimus Spine.

Explore the full profile